Risk for mortality while receiving treatment was similar between medications. HealthDay News — Receipt of methadone for opioid use disorder is associated with a lower risk for treatment ...

Buprenorphine combined with naloxone during pregnancy is associated with lower risks for neonatal abstinence syndrome and neonatal intensive care unit admission than buprenorphine alone. The study ...

Pharmacology, prescribing requirements, and patient preference are crucial factors in choosing opioid agonist treatments.

Credit: Getty Images. Buprenorphine-naloxone may be more cost-effective than extended-release naltrexone as first-line treatment for opioid use disorder. Buprenorphine-naloxone may be more ...

Pregnancies exposed to buprenorphine + naloxone have similar or more favorable neonatal, maternal outcomes as those exposed to buprenorphine alone. HealthDay News — Pregnancies exposed to ...

Medications have become our go-to treatments for opioid addiction. Though life-saving, their downsides are underappreciated ...

Patients with opioid use disorder (OUD) had a lower risk of discontinuing methadone compared with buprenorphine/naloxone, and with a similar mortality risk, according to a population-based cohort ...

People with opioid use disorder in British Columbia who received methadone had a 37- to 40-percent lower rate of treatment discontinuation compared with those who received buprenorphine/naloxone. The ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For pregnant ...

Sanford Health recently installed naloxone (Narcan) distribution boxes in Bemidji and Bagley emergency departments, with the ...

Pregnancies exposed to buprenorphine + naloxone have similar or more favorable neonatal, maternal outcomes as those exposed to buprenorphine alone. HealthDay News — Pregnancies exposed to ...

People with opioid use disorder in British Columbia who received methadone had a 37–40 per cent lower rate of treatment discontinuation compared with those who received buprenorphine/naloxone. The new ...